Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Shares of Clovis Oncology Inc. shot up 17.1% in premarket trading Friday, after the biopharmaceutical company said data from a Phase 3 trial demonstrated that its oral Rubraca "significantly improves" progression-free survival (PFS) compared with standard chemotherapy in patients with advanced, relapsed ovarian cancer. The company said the ARIEL4 study met its primary endpoint of PFS survival, and the safety observed in the study was "highly consistent" with the product labels.

Clovis Oncology stock soars after ovarian cancer treatment meets primary endpoint

The stock price of Clovis Oncology Inc (NASDAQ: CLVS) increased by over 10% pre-market. This is why it happened.

CLVS Stock Price Increases Over 10% Pre-Market: Why It Happened

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca® (rucaparib) will take place today in an oral presentation at the Society of Gynecologic Oncology Virtual Annual Meeting on Women's Cancer (SGO). The data demonstrate that Rubraca significantly improves PFS compared to standard-of-care chemotherapy, including platinum-based chemotherapy, among patients with advanced, relapsed ov

Clovis Oncology's Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation

CLVS stock should attract buyers because declining coronavirus cases offer more opportunities to serve cancer patients. But the economic narrative confirms that the bears may have a point in their pessimism.

Clovis Oncology Survived One Crisis Only to Face Another

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q4 2020 Results - Earnings Call Transcript

Clovis (CLVS) reports wider-than-expected loss for fourth-quarter 2020. Sales of the company's sole marketed drug, Rubraca, increase year over year.

Clovis (CLVS) Q4 Earnings Miss, Revenues Beat, Stock Down

Shares of Clovis Oncology (NASDAQ:CLVS) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 59.12% year over year to ($0.74), which beat the estimate of ($0.77).

Clovis Oncology: Q4 Earnings Insights

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2020, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for 2021. “Despite the evident COVID-related challenges of 2020, we are pleased with our overall sales performance and pipeline progress,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “Most importantly, we advanced our developm

Clovis Oncology Announces 2020 Operating Results

Cenntro Electric Group

Precigen

The next GME will be hard to find, but these three stocks could be solid candidates for a potential short squeeze. The post 3 Troll-able Stocks That Could Be the Next GME appeared first on InvestorPlace.

3 Troll-able Stocks That Could Be the Next GME

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, before the open of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the Company's results in greater detail. The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast wil

Clovis Oncology to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Webcast Conference Call on February 23

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO GU 2021 Virtual Meeting

Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting

Nautilus

Hasbro

XPeng

Hasbro, Nautilus, Clovis Oncology and XPeng were our top stock trades Tuesday. Let's have a look at the charts to see how they're setting up.

4 Top Stock Trades for Tuesday: HAS, CLVS, XPEV, NLS

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that two abstracts featuring data from clinical studies evaluating Rubraca® (rucaparib) in metastatic castration-resistant prostate cancer (mCRPC) and one abstract describing adverse events associated with mCRPC treatment based on real world evidence have been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium to be held virtually, February

Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting

iRobot

SunPower

FuboTV

Unless they were on another planet last week, everybody saw the gigantic moves in companies with huge short interest.

Are These 4 Companies With Massive Short Interest the Next Big Winners?

Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan

Dynavax Technologies

Lannett Company

OPKO Health

Senseonics Holdings

TherapeuticsMD

United Microelectronics

VBI Vaccines

The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's known as a short squeeze.

10 Short Squeeze Candidates Under $10

Despite COVID-19, sales will hit a record for the fourth quarter. Company expecting plenty of milestones concerning its ongoing trials in 2021.

Clovis Oncology: Finally Green Shoots May Be On The Horizon

Morgan Stanley

Procter & Gamble

Halliburton

Morgan Stanley, Halliburton, Procter & Gamble and Clovis Oncology were our top stock trades for Wednesday. Now, let's look at the charts.

4 Top Stock Trades for Wednesday: MS, HAL, PG, CLVS

DHT Holdings

Mustang Bio

RealNetworks

Rolls-Royce Holdings PLC

Penny stocks are cheap for a reason, as there are obvious flaws. However, with those flows comes opportunity.

7 Best Penny Stocks to Buy Early Into 2021

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures. Unaudited preliminary results include: $43.0M - $43.5M in estimated Rubraca® global product revenues for the fourth quarter of 2020 compared to $38.8M

Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020

Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.

Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for FAP-2286, the lead compound in its peptide-targeted radionuclide therapy (PTRT) development program. Following clearance of the INDs by FDA, Clovis plans to initiate a Phase 1/2 clinical study of lutetium-177 labeled FAP-2286 (177Lu-FAP-2286) to determine the dose and

Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial

Clovis' (CLVS) Rubraca achieves significant improvement in progression free survival compared to chemotherapy in late-stage confirmatory study for BRCA-mutated ovarian cancer indication.

Clovis' (CLVS) Rubraca Confirmatory Study Meets Endpoint

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed progression-free survival (InvPFS) compared to chemotherapy in relapsed ovarian cancer patients with a tumor mutation of BRCA who have received two or more prior lines of chemotherapy. “We are pleased with these topline results from the ARIEL4 trial, which confirm the clinical ben

Clovis Oncology's Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

News for Clovis Oncology Stock (CLVS)